Loading
A phase 3 trial of Nogapendekin alfa inbakicept, Tislelizumab and Docetaxel in non-small-cell lung cancer, run by ImmunityBio, Inc., now recruiting.
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In is a phase 3 interventional study registered as NCT06745908 by ImmunityBio, Inc., with 507 participants planned, started 2025-10-01 and due to reach its primary completion in 2028-09. Interventions recorded: N-803, Tislelizumab, Docetaxel and Prior failed checkpoint inhibitor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Cytokines & engineered cytokines and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Tislelizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Docetaxel and the tag pipeline.
Shares Tislelizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/